|
|
| | 5-[[4-[4-[(Dimethylamino)methyl]-3-methyl-1-pyrazolyl]-2-pyrimidinyl]amino]-N,1-dimethyl-1H-indazole-3-carboxamide Basic information |
| | 5-[[4-[4-[(Dimethylamino)methyl]-3-methyl-1-pyrazolyl]-2-pyrimidinyl]amino]-N,1-dimethyl-1H-indazole-3-carboxamide Chemical Properties |
| density | 1.354±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 12.925±0.46(predicted) | | form | Solid | | color | White to off-white |
| | 5-[[4-[4-[(Dimethylamino)methyl]-3-methyl-1-pyrazolyl]-2-pyrimidinyl]amino]-N,1-dimethyl-1H-indazole-3-carboxamide Usage And Synthesis |
| Uses | Syk-IN-4 is a potent, selective and orally bioavailable SYK inhibitor with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers[1]. | | in vivo | Syk-IN-4 exhibits moderate oral bioavailability (60%) following oral administration (1 mg/kg) in male Hans Wistar rats[1].
Syk-IN-4 exhibits high plasma clearance (151 mL/min/kg) combined with large volumes of distribution (1.0 L/kg respectively) following i.v. administration (0.5 mg/kg) in male Hans Wistar rats[1]. | | References | [1] Neil P Grimster, et al. Optimization of a Series of Potent, Selective and Orally Bioavailable SYK Inhibitors. Bioorg Med Chem Lett. 2020 Jul 24;127433. DOI:10.1016/j.bmcl.2020.127433 |
| | 5-[[4-[4-[(Dimethylamino)methyl]-3-methyl-1-pyrazolyl]-2-pyrimidinyl]amino]-N,1-dimethyl-1H-indazole-3-carboxamide Preparation Products And Raw materials |
|